Baseline characteristics of study population
| Characteristic . | Overall, N = 55 . | Intense, n = 36 . | VEN/HMA, n = 19 . | P value . |
|---|---|---|---|---|
| Sex, n (%) | .6 | |||
| Male | 27 (49) | 19 (53) | 8 (42) | |
| Female | 28 (51) | 17 (47) | 11 (58) | |
| Race, n (%) | .8 | |||
| White | 40 (73) | 26 (72) | 14 (74) | |
| Black or African American | 10 (18) | 6 (17) | 4 (21) | |
| Asian/Pacific Islander | 5 (9.1) | 4 (11) | 1 (5.3) | |
| Age at diagnosis, mean (SD) | 67.3 (4.3) | 66.1 (3.9) | 69.6 (4.2) | .005 |
| ECOG, n (%) | .29 | |||
| 0-1 | 43 (81) | 31 (86) | 14 (74) | |
| 2-3 | 10 (19) | 5 (14) | 5 (26) | |
| CCI, mean (SD) | 5.1 (1.8) | 4.5 (0.9) | 6.2 (2.6) | .003 |
| Treatment era, n (%)∗ | .001 | |||
| Treatment era 1 | 36 (65) | 29 (81) | 7 (37) | |
| Treatment era 2 | 19 (35) | 7 (19) | 12 (63) | |
| WBC count at diagnosis, ×103/μL, mean (SD) | 65 (78) | 74 (82) | 47 (67) | .12 |
| Extramedullary disease present, n (%) | 18 (33) | 12 (33) | 6 (32) | .9 |
| Therapy-related, n (%) | 7 (13) | 4 (11) | 3 (16) | .7 |
| Myelodysplastic-related†, n (%) | 14 (25) | 10 (28) | 4 (21) | .7 |
| MDS-associated mutation‡, n (%) | 17 (45) | 8 (38) | 9 (53) | .4 |
| FLT3-TKD mutated, n (%) | 19 (35) | 12 (33) | 7 (37) | .8 |
| DNMT3A mutated, n (%) | 16 (29) | 8 (22) | 8 (42) | .12 |
| IDH2 mutated, n (%) | 15 (27) | 7 (19) | 8 (42) | .07 |
| IDH1 mutated, n (%) | 12 (22) | 8 (22) | 4 (21) | >.9 |
| TET2 mutated, n (%) | 9 (16) | 4 (11) | 5 (26) | .2 |
| NRAS mutated, n (%) | 7 (13) | 7 (19) | 0 (0) | .08 |
| WT1 mutated, n (%) | 4 (7.3) | 3 (8.3) | 1 (5.3) | >.9 |
| PTPN11 mutated, n (%) | 4 (7.3) | 3 (8.3) | 1 (5.3) | >.9 |
| Characteristic . | Overall, N = 55 . | Intense, n = 36 . | VEN/HMA, n = 19 . | P value . |
|---|---|---|---|---|
| Sex, n (%) | .6 | |||
| Male | 27 (49) | 19 (53) | 8 (42) | |
| Female | 28 (51) | 17 (47) | 11 (58) | |
| Race, n (%) | .8 | |||
| White | 40 (73) | 26 (72) | 14 (74) | |
| Black or African American | 10 (18) | 6 (17) | 4 (21) | |
| Asian/Pacific Islander | 5 (9.1) | 4 (11) | 1 (5.3) | |
| Age at diagnosis, mean (SD) | 67.3 (4.3) | 66.1 (3.9) | 69.6 (4.2) | .005 |
| ECOG, n (%) | .29 | |||
| 0-1 | 43 (81) | 31 (86) | 14 (74) | |
| 2-3 | 10 (19) | 5 (14) | 5 (26) | |
| CCI, mean (SD) | 5.1 (1.8) | 4.5 (0.9) | 6.2 (2.6) | .003 |
| Treatment era, n (%)∗ | .001 | |||
| Treatment era 1 | 36 (65) | 29 (81) | 7 (37) | |
| Treatment era 2 | 19 (35) | 7 (19) | 12 (63) | |
| WBC count at diagnosis, ×103/μL, mean (SD) | 65 (78) | 74 (82) | 47 (67) | .12 |
| Extramedullary disease present, n (%) | 18 (33) | 12 (33) | 6 (32) | .9 |
| Therapy-related, n (%) | 7 (13) | 4 (11) | 3 (16) | .7 |
| Myelodysplastic-related†, n (%) | 14 (25) | 10 (28) | 4 (21) | .7 |
| MDS-associated mutation‡, n (%) | 17 (45) | 8 (38) | 9 (53) | .4 |
| FLT3-TKD mutated, n (%) | 19 (35) | 12 (33) | 7 (37) | .8 |
| DNMT3A mutated, n (%) | 16 (29) | 8 (22) | 8 (42) | .12 |
| IDH2 mutated, n (%) | 15 (27) | 7 (19) | 8 (42) | .07 |
| IDH1 mutated, n (%) | 12 (22) | 8 (22) | 4 (21) | >.9 |
| TET2 mutated, n (%) | 9 (16) | 4 (11) | 5 (26) | .2 |
| NRAS mutated, n (%) | 7 (13) | 7 (19) | 0 (0) | .08 |
| WT1 mutated, n (%) | 4 (7.3) | 3 (8.3) | 1 (5.3) | >.9 |
| PTPN11 mutated, n (%) | 4 (7.3) | 3 (8.3) | 1 (5.3) | >.9 |
FLT3-TKD, FLT3- tyrosine kinase domain; MDS, myelodysplastic syndrome; SD, standard deviation.
Treatment era 1 are patients with first treatment date before 20 October 2020. Treatment era 2 are patients with first treatment date on or after 20 October 2020.
Myelodysplastic-related refers to patients with AML arising out of prior MDS or MDS/myeloproliferative neoplasm. Because these are favorable risk, by definition they do not have MDS-related cytogenetic changes.
MDS-associated mutations are ASXL1, BCOR, EZH2, RUNX1, SF3B1, SRSF2, STAG2, U2AF1, and ZRSR2.